You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Design Combined Effects Explosives (CEX) Using Numerical Simulations

    SBC: COMBUSTION RESEARCH & FLOW TECHNOLOGY INC            Topic: DTRA122006

    Combustion Research and Flow Technology, Inc. (CRAFT Tech) and Prof. Glumac of the University of Illinois at Urbana-Champaign (UIUC) have teamed up to provide DTRA with an innovative approach to develop new combined effects explosives (CEX) formulations. CEX represent a class of recently-developed aluminized explosives seeking to provide the performance of both (i) high-energy explosives and (ii) ...

    SBIR Phase I 2013 Department of DefenseDefense Threat Reduction Agency
  2. Novel Extensible Design Approaches for Advanced Aircraft Composite Structural Architectures (MSC P4135)

    SBC: MATERIALS SCIENCES LLC            Topic: ST13A006

    Among the factors that inhibit the use of composite materials in both general aviation aircraft and DoD platforms are the high cost of engineering and the cost of certification. Unless manufacturers can control risk when introducing new materials and pro

    STTR Phase I 2013 Department of DefenseDefense Advanced Research Projects Agency
  3. Novel schemes for highly reliable aerospace electromechanical primary actuation systems

    SBC: LCDRIVES CORP.            Topic: SB132005

    There is a need to achieve 10^-9 reliability for actuators for critical aerospace applications and this precludes single point failure for all but the simplest and most reliable electrical and mechanical components. LC Drives proposes a method of constructing a high reliability linear actuator for critical aerospace applications that is designed such that jams caused by conventional electrical a ...

    SBIR Phase I 2013 Department of DefenseDefense Advanced Research Projects Agency
  4. Looking Glass

    SBC: Intific, Inc.            Topic: 004

    Looking Glass is an immersive, story-driven game experience that enables computer science education for students K-12. It presents learning in a game-based series of challenge levels that permit a high degree of player choice in tailoring educational progression and adapting game systems that present both STEM and SEL interactions. Gameplay occurs within a futuristic Wonderland, where proficiency ...

    SBIR Phase I 2013 Department of DefenseDefense Advanced Research Projects Agency
  5. Novel liver fibrosis test for early detection and classification

    SBC: IMMUNOTOPE, INC.            Topic: NIAAA

    DESCRIPTION (provided by applicant): The overall goal of this application is to develop and validate a potential biomarker based assay to determine if it can be used as a noninvasive test to detect the stage of hepatic fibrosis and to predict fibrosis progression in HIV/HCV co-infected patients. Significant fibrosis and cirrhosis are premalignant conditions that greatly increase the risk of the de ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. A Diarylheptanoid Scaffold to Treat Taopathies

    SBC: ALS BIOPHARMA, LLC            Topic: NIA

    DESCRIPTION: We identified the Myrica cerifera (Southern Bayberry) extract using a systematic screen as a potent reducer of the structural protein tau, which accumulates in a group of diseases called the tauopathies . The most prevalent tauopathy is Alzheimer's disease, for which there is renewed interest in the identification of tau- based therapeutic approaches to treat this devastating d ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. DC-SIGN Inhibitors for the Treatment of HIV Infection

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): DC-SIGN (dendritic cell specific ICAM-3-grabbing non-integrin), a membrane protein of C-type lectin family, is found in high levels on monocyte-derived DCs, some macrophages, and activated B cells. In vivo, DC-SIGN- positive cells were demonstrated in lymph nodes, tonsils, skin, and the subepithelial region of the cervix. DC- SIGN has been shown to bind to a nu ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. New therapeutics for the treatment of Acinetobactor baumannii infections.

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Acinetobacter are strictly aerobic, non-fermentative Gram-negative bacilli that are of major concern in human health, in particular the species Acinetobacter baumannii. They are responsible for clinically important infections that cause a wide variety of maladies including pneumonia, skin and wound infections, bacteremia and meningitis. In addition, A. baumanni ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Polaris Oncology Survivor Transition (POST) System

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: NCI

    DESCRIPTION (provided by applicant): The Institute of Medicine (IOM) strongly recommends that all breast cancer patients who are ending active treatment have a survivorship plan. Such a plan should assist patients in moving back to their primary care physician (PCP), provide advice for reducing risk for cancer recurrence or new cancer development, and address the remaining psychosocial challenge ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Inhibitors of IgH Gene Enhancers for the Treatment of Multiple Myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: NCI

    DESCRIPTION (provided by applicant): Multiple Myeloma (MM) is a deadly plasma cell malignancy. Treatment advances have improved clinical outcomes over the past decade, but the disease remains incurable, thus creating a need for new and innovative treatmentoptions. The MM drug pipeline includes several proteasome inhibitors and immunomodulatory agents, and other classes of agents that target signal ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government